Low-dose of oral factor Xa inhibitors in patients with a recent acute coronary syndrome: A systematic review and meta-analysis of randomized trials

Atherosclerosis

Volumn 229, Issue 2, 2013, Pages 482-488

  Obonska, Karolina ^a   Navarese, Eliano Pio ^a   Lansky, Alexandra ^b   Tarantini, Giuseppe ^c   Rossini, Roberta ^d   Kozinski, Marek ^a   Musumeci, Giuseppe ^d   Di Pasquale, Giuseppe ^e   Górny, Bartosz ^a   Szczesniak, Anna ^a   Kowalewski, Mariusz ^a   Gurbel, Paul Alfred ^f   Kubica, Jacek ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^d OSPEDALI RIUNITI   (Italy)

^e MAGGIORE HOSPITAL   (Italy)

^f SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

Author keywords

ACS; Acute coronary syndrome; BID; HR; Meta analysis; MI; OR; Oral anti Xa anticoagulants; QD; RCTs; TIMI; Xa

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DAREXABAN; PLACEBO; PRASUGREL; RIVAROXABAN; TICAGRELOR;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CARDIOVASCULAR MORTALITY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; KIDNEY FAILURE; META ANALYSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SENSITIVITY ANALYSIS; ST SEGMENT DEPRESSION; ST SEGMENT ELEVATION; STANDARD; SYSTEMATIC REVIEW;

ACS; ACUTE CORONARY SYNDROME; BID; HAZARD RATIO; HR; META-ANALYSIS; MI; MYOCARDIAL INFARCTION; ODDS RATIO; ONCE DAILY; OR; ORAL ANTI XA ANTICOAGULANTS; QD; RANDOMIZED CONTROLLED TRIALS; RCTS; THROMBOLYSIS IN MYOCARDIAL INFARCTION; TIMI; TWICE PER DAY; X ACTIVATED; XA;

ACUTE CORONARY SYNDROME; ADMINISTRATION, ORAL; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84880630031     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.04.022     Document Type: Review

References (39)

1. Hamm C.W., Bassand J.P., Agewall S., et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011, 32:2999-3054.
2. Roger V.L., Go A.S., Lloyd-Jones D.M., et al. Executive summary: heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012, 125:188-197.
3. Polonski L., Gasior M., Gierlotka M., et al. Acomparison of ST elevation versus non-ST elevation myocardial infarction outcomes in a large registry database: are non-ST myocardial infarctions associated with worse long-term prognoses?. Int J Cardiol 2011, 152(1):70-77.
4. Merlini P.A., Bauer K.A., Oltrona L., et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994, 90:61-68.
5. Rothberg M.B., Celestin C., Fiore L.D., Lawler E., Cook J.R. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med 2005, 143:241-250.
6. Ardissino D., Merlini P.M., Bauer K.A., et al. Coagulation activation and long-term outcome in acute coronary syndromes. Blood 2003, 102:2731-2735.
7. Christersson C., Oldgren J., Bylock A., Wallentin L., Siegbahn A. Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction. JThromb Haemost 2005, 3:2245-2253.
8. Cohen M., Adams P.C., Parry G., et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: primary end points analysis from the ATACS Trial. Circulation 1994, 89:81-88.
9. Cohen M., Adams P.C., Hawkins L., Bach M., Fuster V. Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). Am J Cardiol 1990, 66:1287-1292.
10. Van Es R.F., Jonker J.J., Verheugt F.W., Deckers J.W., Grobbee D.E. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 2002, 360:109-113.
11. Brouwer M.A., van den Bergh P.J., Aengevaeren W.R., et al. Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the antithrombotics in the prevention of reocclusion in coronary thrombolysis (APRICOT)-2 trial. Circulation 2002, 106:659-665.
12. Huynh T., Theroux P., Bogaty P., Nasmith J., Solymoss S. Aspirin, warfarin, or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation 2001, 103:3069-3074.
13. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. JAm Coll Cardiol 2001, 37:475-484.
14. Anand S.S., Yusuf S., Pogue J., Weitz J.I., Flather M. Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results. Circulation 1998, 98:1064-1070.
15. Hurlen M., Abdelnoor M., Smith P., Erikssen J., Arnesen H. Warfarin, aspirin, or both after myocardial infarction. NEngl J Med 2002, 347:969-974.
16. Williams M.J., Morison I.M., Parker J.H., Stewart R.A. Progression of the culprit lesion in unstable coronary artery disease with warfarin and aspirin versus aspirin alone: preliminary study. JAm Coll Cardiol 1997, 30:364-369.
17. Anand S.S., Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAm Med Assoc 1999, 282:2058-2067.
18. Andreotti F., Testa L., Biondi-Zoccai G.G., Crea F. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25 307 patients. Eur Heart J 2006, 27:519-526.
19. Hirsh J. Oral anticoagulant drugs. NEngl J Med 1991, 324:1865-1875.
20. Ansell J., Hirsh J., Poller L., Bussey H., Jacobson A., Hylek E. The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004, 126:204S-233S.
21. Eikelboom W., Weitz J.I. Areplacement for warfarin: the search continues. Circulation 2007, 116:131-133.
22. Mega J.L., Braunwald E., Mohanavelu S., et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACSTIMI 46): a randomised, double-blind, phase II trial. Lancet 2009, 374:29-38.
23. Mega J.L., Braunwald E., Wiviott S.D., et al. Rivaroxaban in patients with a recent acute coronary syndrome. NEngl J Med 2012, 366:9-19.
24. Alexander J.H., Becker R.C., Bhatt D.L., et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 2009, 119:2877-2885.
25. Alexander J.H., Lopes R.D., James S., et al. Apixaban with antiplatelet therapy after acute coronary syndrome. NEngl J Med 2011, 365:699-708.
26. Steg P.G., Mehta S.R., Jukema J.W., et al. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J 2011, 32:2541-2554.
27. The Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions. Available from: [updated August 2012]. http://www.cochrane.%20org/resources/handbook/.
28. Liberati A., Altman D.G., Tetzlaff J., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explana-tion and elaboration. Br Med J 2009, 339:2700.
29. Weitz J.I., Hirsh J., Samama M.M. New antithrombotic drugs: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008, 133:234S-256S.
30. Herault J.P., Bernat A., Pflieger A.M., Lormeau J.C., Herbert J.M. Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase. JPharmacol Exp Ther 1997, 283:16-22.
31. Komócsi A., Vorobcsuk A., Kehl D., Aradi D. Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 2012 Sep 24, 1-9. [ahead of print]. 10.1001/archinternmed.2012.4026.
32. Eikelboom J.W., Mehta S.R., Anand S.S., Xie C., Fox K.A., Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006, 114:774-782.
33. Moscucci M., Fox K.A., Cannon C.P., et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003, 24:1815-1823.
34. Segev A., Strauss B.H., Tan M., et al. Canadian Acute Coronary Syndromes Registries Investigators. Predictors and 1-year outcome of major bleeding in patients with non-ST-elevation acute coronary syndromes: insights from the Canadian Acute Coronary Syndrome Registries. Am Heart J 2005, 150:690-694.
35. Fitchett D. The impact of bleeding in patients with acute coronary syndromes: how to optimize the benefits of treatment and minimize the risk. Can J Cardiol 2007, 23:663-671.
36. Janssen Pharmaceuticals FDA issues complete response letter for Xarelto (rivaroxaban) for the reduction of secondary cardiovascular events in patients with acute coronary syndrome June 21, 2012, [press release].
37. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. NEngl J Med 2011, 365:981-992.
38. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. NEngl J Med 2011, 365:883-889.
39. Miller R. Missing data lead FDA panel to vote against rivaroxaban for ACS. http://www.theheart.org/article/1405663.do.